New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials
홍정희,
소속 상세정보
홍정희 ( Hong Jeong-Hee )
Dankook University College of Medicine Department of Urology
Abstract
Bone metastasis is a common sign of disease progression in nonmetastatic castration-resistant prostate cancer (nmCRPC). It has been known to be associated with significant morbidity and mortality. Delaying or preventing development of distant metastasis is the ideal goal of treatment. There had been no standard treatment options available for patients with nmCRPC before 2018. Recent approval of new androgen receptor axis-targeted agents in the management of nmCRPC has led to rapid evolution and is worthy of detailed investigation.
키워드
Castration-resistant prostate neoplasms; Neoplasm metastasis; Androgen receptor antagonists
원문 및 링크아웃 정보
등재저널 정보